MA53721A - Modulateurs de la monoacylglycérol lipase - Google Patents

Modulateurs de la monoacylglycérol lipase

Info

Publication number
MA53721A
MA53721A MA053721A MA53721A MA53721A MA 53721 A MA53721 A MA 53721A MA 053721 A MA053721 A MA 053721A MA 53721 A MA53721 A MA 53721A MA 53721 A MA53721 A MA 53721A
Authority
MA
Morocco
Prior art keywords
monoacylglycerol lipase
modulators
lipase modulators
monoacylglycerol
lipase
Prior art date
Application number
MA053721A
Other languages
English (en)
Inventor
Michael K Ameriks
Gang Chen
Chaofeng Huang
Brian Ngo Laforteza
Suchitra Ravula
Emma Helen Southgate
Wei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53721A publication Critical patent/MA53721A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
MA053721A 2018-09-28 2019-09-27 Modulateurs de la monoacylglycérol lipase MA53721A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862738600P 2018-09-28 2018-09-28

Publications (1)

Publication Number Publication Date
MA53721A true MA53721A (fr) 2021-09-15

Family

ID=68109428

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053721A MA53721A (fr) 2018-09-28 2019-09-27 Modulateurs de la monoacylglycérol lipase

Country Status (26)

Country Link
US (3) US20200102303A1 (fr)
EP (1) EP3856178B1 (fr)
JP (2) JP7482116B2 (fr)
KR (1) KR102911066B1 (fr)
CN (1) CN113164459B (fr)
AU (2) AU2019350624B2 (fr)
BR (1) BR112021005896A2 (fr)
CA (1) CA3111380A1 (fr)
CL (1) CL2021000757A1 (fr)
CO (1) CO2021003944A2 (fr)
CR (1) CR20210153A (fr)
DO (1) DOP2021000051A (fr)
EA (1) EA202190886A1 (fr)
EC (1) ECSP21021381A (fr)
IL (1) IL281812A (fr)
JO (1) JOP20210058A1 (fr)
MA (1) MA53721A (fr)
MX (1) MX2021003737A (fr)
MY (1) MY205440A (fr)
NI (1) NI202100023A (fr)
PE (1) PE20211773A1 (fr)
PH (1) PH12021550659A1 (fr)
SA (2) SA522441561B1 (fr)
SG (1) SG11202102281VA (fr)
TW (1) TWI863931B (fr)
WO (1) WO2020065613A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
JP7837120B2 (ja) * 2019-06-04 2026-03-30 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのピラゾール及びイミダゾール誘導体、組成物、並びに方法
AU2020358948A1 (en) * 2019-09-30 2022-05-26 Janssen Pharmaceutica Nv Radiolabelled MGL PET ligands
BR112022019077A2 (pt) * 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
WO2022150962A1 (fr) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Inhibiteurs de protéase, leur préparation et leurs utilisations
KR20240046550A (ko) * 2021-08-11 2024-04-09 란도스 바이오파마, 인크. Nlrx1의 테트라히드로피라졸로피리딘-유사체 리간드 및 그의 용도
CN118488953A (zh) 2021-12-16 2024-08-13 豪夫迈·罗氏有限公司 用作单酰基甘油脂肪酶抑制剂的双环杂环化合物
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
CN115872995B (zh) * 2022-12-27 2024-10-01 上海凌凯科技股份有限公司 一种吡唑并吡啶化合物及一种羧酸衍生物的制备方法
CN116606298A (zh) * 2023-05-26 2023-08-18 康化（上海）新药研发有限公司 2,3-二氢-[1,4]二噁烷并[2,3-b]吡啶-8-羧酸的合成方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA2093125C (fr) 1990-10-02 2003-12-16 Warner-Lambert Company Antagonistes de l'angiotensine ii
EP1527074A1 (fr) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles actifs inhibiteurs de kinase, procede de preparation et compositions pharmaceutiques contenant ceux-ci
CA2493625A1 (fr) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles actifs utiles comme inhibiteurs de kinase, leur procede de preparation et compositions pharmaceutiques les comprenant
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
FR2857363B1 (fr) 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
AU2004276341B2 (en) 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
CA2576465A1 (fr) 2004-08-23 2006-03-02 Merck & Co., Inc. Derives de triazole accoles inhibiteurs de la dipeptidyl peptidase-iv utilises dans le traitement ou la prevention du diabete
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (fr) 2005-04-11 2006-10-19 Abbott Laboratories Antagonistes de l'acylhydrazide p2x7 et leurs utilisations
MX2008012617A (es) 2006-03-31 2008-10-10 Novartis Ag Compuestos organicos.
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
FR2915197B1 (fr) 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
JP2010530427A (ja) 2007-06-21 2010-09-09 シェーリング コーポレイション 多環式グアニン誘導体およびその使用方法
SG183699A1 (en) 2007-08-10 2012-09-27 Lundbeck & Co As H Heteroaryl amide analogues
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
KR101598397B1 (ko) 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
WO2010066629A2 (fr) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Nouvelles azaindoles
AU2010239188B2 (en) 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
BRPI1014874A2 (pt) * 2009-04-22 2016-04-12 Janssen Pharmaceutica Nv piperazinil azetidinil amidas heteroaromáticas e aromáticas como inibidores de monoacilglicerol lipase
US8501946B2 (en) 2009-04-29 2013-08-06 Glaxo Group Limited 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
WO2011050202A1 (fr) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Composés hétérocycliques condensés en tant que modulateurs de récepteur d'orexine
WO2011103715A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Antagonistes de canal task
EP2552920B1 (fr) 2010-04-02 2017-03-15 Ogeda Sa Nouveaux composés antagonistes sélectifs du récepteur nk-3, composition pharmaceutique et procédé pour une utilisation dans des troubles médiés par les récepteurs nk-3
WO2011128769A2 (fr) 2010-04-16 2011-10-20 Rodrigo Graf Fernandez Structures pliables pour une construction
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012040048A2 (fr) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones comme antagonistes des récepteurs p2x7
AU2011307252B2 (en) * 2010-09-27 2015-06-25 Janssen Pharmaceutica Nv Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
CN103260703A (zh) 2010-10-22 2013-08-21 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺
CA2815353A1 (fr) 2010-10-22 2012-04-26 Janssen Pharmaceutica Nv Amino-pyrrolidine-azetidine diamides utilises comme inhibiteurs de la monoacylglycerol lipase
WO2012145581A1 (fr) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Octahydropyrrolo [3,4-c] pyrroles disubstitués utilisés comme modulateurs du récepteur de l'orexine
HUE028858T2 (hu) 2011-10-03 2017-01-30 Euroscreen Sa Új királis N-acil-5,6,7,(8-szubsztituált)-tetrahidro-[1,2,4]triazolo[4,3-A]pirazinok mint szelektív NK-3 receptor antagonisták, gyógyászati készítmény és eljárások NK-3 receptor által közvetített rendellenességek során történõ alkalmazásra
EP2899183B1 (fr) * 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur Xia
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
JP5205547B1 (ja) 2012-04-20 2013-06-05 株式会社ノイズ研究所 放射信号可視化装置
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
BR112014029161A2 (pt) 2012-05-22 2017-06-27 Genentech Inc benzamidas n-substituídas e seu uso no tratamento de dor
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
JP6466335B2 (ja) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−γ−Ｔのメチレン連結キノリニルモジュレーター
JP6359546B2 (ja) 2012-11-01 2018-07-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CA2895808A1 (fr) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Inhibiteurs d'histone demethylase
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
RS59909B1 (sr) 2013-03-06 2020-03-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
ES2704048T3 (es) 2013-03-14 2019-03-14 Glaxosmithkline Ip No 2 Ltd Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EA201591610A1 (ru) 2013-03-14 2015-12-30 Курадев Фарма Прайвит Лтд. Ингибиторы кинуренинового пути
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
EP2970271B1 (fr) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV Modulateurs de p2x7
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
CA2907814C (fr) 2013-03-29 2021-07-13 Euroscreen Sa Nouvelles n-acyl-(3-substitues)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines utilisees en tant qu'antagonistes selectifs des recepteurs nk-3, composition pharmaceutique, methodes d'utilisation dans le traitement de troubles medies par les recepteurs nk-3
MX2016002241A (es) 2013-08-22 2016-05-31 Hoffmann La Roche Alcoholes de alquinilo y metodos de uso.
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
JP6625616B2 (ja) 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン
WO2016039977A1 (fr) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv Modulateurs de p2x7
US9527845B2 (en) 2014-12-30 2016-12-27 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
WO2016158956A1 (fr) 2015-03-30 2016-10-06 武田薬品工業株式会社 Composé hétérocyclique
HK1249101A1 (zh) 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
WO2017087858A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN110035995A (zh) 2016-12-16 2019-07-19 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
EP3571202B1 (fr) 2017-01-23 2021-06-30 Pfizer Inc. Composés spiro hétérocycliques utilisés en tant qu'inhibiteurs de magl
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
WO2020211798A1 (fr) 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 Inhibiteur contenant un dérivé d'anneau bicyclique, et son procédé de préparation et ses utilisations
AU2020358948A1 (en) 2019-09-30 2022-05-26 Janssen Pharmaceutica Nv Radiolabelled MGL PET ligands
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase

Also Published As

Publication number Publication date
NI202100023A (es) 2021-09-07
AU2019350624B2 (en) 2025-07-24
AU2025226693A1 (en) 2025-09-25
WO2020065613A1 (fr) 2020-04-02
SG11202102281VA (en) 2021-04-29
BR112021005896A2 (pt) 2021-07-27
US11820766B2 (en) 2023-11-21
KR102911066B1 (ko) 2026-01-09
AU2019350624A1 (en) 2021-03-18
CL2021000757A1 (es) 2021-08-27
CR20210153A (es) 2021-05-11
US20230145249A1 (en) 2023-05-11
DOP2021000051A (es) 2022-05-31
SA522441561B1 (ar) 2024-08-11
PE20211773A1 (es) 2021-09-08
CO2021003944A2 (es) 2021-04-19
JOP20210058A1 (ar) 2021-03-24
EP3856178A1 (fr) 2021-08-04
MY205440A (en) 2024-10-21
JP2022502424A (ja) 2022-01-11
PH12021550659A1 (en) 2022-02-21
KR20210069080A (ko) 2021-06-10
TWI863931B (zh) 2024-12-01
CN113164459A (zh) 2021-07-23
CA3111380A1 (fr) 2020-04-02
US20200102303A1 (en) 2020-04-02
TW202028198A (zh) 2020-08-01
CN113164459B (zh) 2024-09-03
JP2024096702A (ja) 2024-07-17
JP7482116B2 (ja) 2024-05-13
US12577243B2 (en) 2026-03-17
ECSP21021381A (es) 2021-04-29
MX2021003737A (es) 2021-05-14
IL281812A (en) 2021-05-31
SA521421575B1 (ar) 2024-08-11
EP3856178B1 (fr) 2026-03-11
US20220332713A1 (en) 2022-10-20
EA202190886A1 (ru) 2021-09-07

Similar Documents

Publication Publication Date Title
IL281812A (en) Monoacylglycerol lipase modulators
DK3743406T3 (da) Tmem16a modulatorer
EP3861130A4 (fr) Modulateurs génétiques modifiés
MA53722A (fr) Modulateurs de la monoacylglycérol lipase
IL283967A (en) Modulators of hsd17b13 expression
IL281492A (en) Modulators of pnpla3 expression
MA54386A (fr) Modulateurs de trex1
EP4103557C0 (fr) Modulateurs de la monoacylglycérol lipase
EP3675849A4 (fr) Modulateurs de tétrahydrocannabinol
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
DK3749669T6 (da) Ahr-modulatorer
MA53924A (fr) Modulateurs de l'expression d'apol1
HUE058145T2 (hu) Deformálható érzékelõ
MA54825A (fr) Modulateurs de gpr35
EP3821026A4 (fr) Enzymes variantes de phosphopentomutase modifiées
EP4192957A4 (fr) Modulateurs de trpml
EP3758704A4 (fr) Modulateurs de l'expression d'irf4
EP3948021A4 (fr) Boîte de vitesses
EP4025957C0 (fr) Modulateur électro-optique
EP4035739A4 (fr) Hydrogel
EP3777974C0 (fr) Applicateur de lumière
EP3779540A4 (fr) Modulateur optique
EP3954003A4 (fr) Épissure de contact
EP4022049A4 (fr) Variants de lipase modifiés
EP3942038A4 (fr) Modulateurs de tdp-43